EUVIMEDEUVIMED entdecken
Crossref

Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration

Kaho Shirai, Takahiro Suzuki, Yuka Nagakura, Tetsuya Honda

European Journal of Dermatology · 2026-06 · 36 (3) · 277-279

DOI: 10.1684/ejd.2026.5084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2026-06. Verfasst von Kaho Shirai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Deprtment of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Deprtment of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
  • Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

Zitieren

APA

Shirai, K., Suzuki, T., Nagakura, Y., & Honda, T. (2026). Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration. European Journal of Dermatology, 36(3), 277-279. https://doi.org/10.1684/ejd.2026.5084

Vancouver

Shirai K, Suzuki T, Nagakura Y, Honda T. Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration. European Journal of Dermatology. 2026;36(3):277-279. doi:10.1684/ejd.2026.5084

BibTeX
@article{Shirai2026,
  author = {Shirai, Kaho and Suzuki, Takahiro and Nagakura, Yuka and Honda, Tetsuya},
  title = {Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration},
  journal = {European Journal of Dermatology},
  year = {2026},
  volume = {36},
  number = {3},
  pages = {277--279},
  doi = {10.1684/ejd.2026.5084}
}
Kostenlos starten →